These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 27603432)

  • 1. Early fast-acting treatment strategy against generalized myasthenia gravis.
    Utsugisawa K; Nagane Y; Akaishi T; Suzuki Y; Imai T; Tsuda E; Minami N; Uzawa A; Kawaguchi N; Masuda M; Konno S; Suzuki H; Murai H; Aoki M
    Muscle Nerve; 2017 Jun; 55(6):794-801. PubMed ID: 27603432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of early cycles of fast-acting treatment in generalised myasthenia gravis.
    Uzawa A; Suzuki S; Kuwabara S; Akamine H; Onishi Y; Yasuda M; Ozawa Y; Kawaguchi N; Kubota T; Takahashi MP; Suzuki Y; Watanabe G; Kimura T; Sugimoto T; Samukawa M; Minami N; Masuda M; Konno S; Nagane Y; Utsugisawa K
    J Neurol Neurosurg Psychiatry; 2023 Jun; 94(6):467-473. PubMed ID: 36693723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral corticosteroid dosing regimen and long-term prognosis in generalised myasthenia gravis: a multicentre cross-sectional study in Japan.
    Imai T; Utsugisawa K; Murai H; Tsuda E; Nagane Y; Suzuki Y; Minami N; Uzawa A; Kawaguchi N; Masuda M; Konno S; Suzuki H; Akaishi T; Aoki M
    J Neurol Neurosurg Psychiatry; 2018 May; 89(5):513-517. PubMed ID: 29175893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationale for the clinical guidelines for myasthenia gravis in Japan.
    Murai H; Utsugisawa K; Nagane Y; Suzuki S; Imai T; Motomura M
    Ann N Y Acad Sci; 2018 Feb; 1413(1):35-40. PubMed ID: 29377151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Early Treatment with Intravenous High-Dose Methylprednisolone for Ocular Myasthenia Gravis.
    Uzawa A; Suzuki S; Kuwabara S; Akamine H; Onishi Y; Yasuda M; Ozawa Y; Kawaguchi N; Kubota T; Takahashi MP; Suzuki Y; Watanabe G; Kimura T; Sugimoto T; Samukawa M; Minami N; Masuda M; Konno S; Nagane Y; Utsugisawa K
    Neurotherapeutics; 2023 Mar; 20(2):518-523. PubMed ID: 36607596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral corticosteroid therapy and present disease status in myasthenia gravis.
    Imai T; Suzuki S; Tsuda E; Nagane Y; Murai H; Masuda M; Konno S; Suzuki Y; Nakane S; Fujihara K; Suzuki N; Utsugisawa K
    Muscle Nerve; 2015 May; 51(5):692-6. PubMed ID: 25155615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognosis of Ocular Myasthenia Gravis: Retrospective Multicenter Analysis.
    Nagia L; Lemos J; Abusamra K; Cornblath WT; Eggenberger ER
    Ophthalmology; 2015 Jul; 122(7):1517-21. PubMed ID: 25892018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of early prednisolone treatment on the generalization rate in ocular myasthenia gravis.
    Zach H; Cetin H; Hilger E; Paul A; Wuschitz B; Jung R; Auff E; Zimprich F
    Eur J Neurol; 2013 Apr; 20(4):708-13. PubMed ID: 23279780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Social disadvantages associated with myasthenia gravis and its treatment: a multicentre cross-sectional study.
    Nagane Y; Murai H; Imai T; Yamamoto D; Tsuda E; Minami N; Suzuki Y; Kanai T; Uzawa A; Kawaguchi N; Masuda M; Konno S; Suzuki H; Aoki M; Utsugisawa K
    BMJ Open; 2017 Feb; 7(2):e013278. PubMed ID: 28235967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does perioperative high-dose prednisolone have clinical benefits for generalized myasthenia gravis?
    Sekine Y; Kawaguchi N; Hamada C; Sekiguchi H; Yasufuku K; Iyoda A; Shibuya K; Fujisawa T
    Eur J Cardiothorac Surg; 2006 Jun; 29(6):908-13. PubMed ID: 16675232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Demographic and clinical characteristics of patients with myasthenia gravis].
    Rastenyte D; Vaitkus A; Neverauskas R; Pauza V
    Medicina (Kaunas); 2002; 38(6):611-6. PubMed ID: 12474667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term follow up of thymus in patients with myasthenia gravis.
    Sugawara M; Wada C; Okawa S; Kobayashi M; Abe E; Obara K; Kamada S; Ohnishi H; Toyoshima I
    J Neuroimmunol; 2010 Apr; 221(1-2):121-4. PubMed ID: 20110131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term outcomes and prognostic factors in generalized myasthenia gravis.
    Ozawa Y; Uzawa A; Yasuda M; Kojima Y; Onishi Y; Oda F; Kanai T; Himuro K; Kawaguchi N; Kuwabara S
    J Neurol; 2021 Oct; 268(10):3781-3788. PubMed ID: 33774750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical efficacy and cytokine network-modulating effects of tacrolimus in myasthenia gravis.
    Furukawa Y; Yoshikawa H; Iwasa K; Yamada M
    J Neuroimmunol; 2008 Mar; 195(1-2):108-15. PubMed ID: 18262659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Therapeutic strategies against myasthenia gravis].
    Utsugisawa K; Nagane Y
    Nihon Rinsho; 2013 May; 71(5):881-6. PubMed ID: 23777099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-thymectomy combined treatment of prednisone and tacrolimus versus prednisone alone for consolidation of complete stable remission in patients with myasthenia gravis: a non-randomized, non-controlled study.
    Ponseti JM; Gamez J; Azem J; Fort JM; López-Cano M; Vilallonga R; Buera M; Armengol M
    Curr Med Res Opin; 2007 Jun; 23(6):1269-78. PubMed ID: 17559724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Utility of Acetylcholine Receptor Antibody Testing in Ocular Myasthenia Gravis.
    Peeler CE; De Lott LB; Nagia L; Lemos J; Eggenberger ER; Cornblath WT
    JAMA Neurol; 2015 Oct; 72(10):1170-4. PubMed ID: 26258604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decompensating esophoria as the presenting feature of myasthenia gravis.
    Arblaster GE; Shipman TL; Pepper IM
    J AAPOS; 2009 Jun; 13(3):310-1. PubMed ID: 19395293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab for myasthenia gravis: three case reports and review of the literature.
    Stieglbauer K; Topakian R; Schäffer V; Aichner FT
    J Neurol Sci; 2009 May; 280(1-2):120-2. PubMed ID: 19272616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subclinical cardiac involvement in thymomatous Myasthenia Gravis.
    Giallafos E; Zouvelou V; Maurogeni S; Stamboulis E
    Hellenic J Cardiol; 2016; 57(5):345-347. PubMed ID: 28185979
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.